Literature DB >> 11053752

Experimental study of the effects of Optison concentration on sonoporation in vitro.

M Ward1, J Wu, J F Chiu.   

Abstract

Lethal sonoporation and reparable sonoporation were observed in Jurkat lymphocytes in suspension with the addition of varying amounts of Optison, a commercially available bubble-based contrast agent. For given ultrasound (US) exposure conditions (spatial peak-pressure amplitude of 0.2 MPa, duty cycle 10% and 2-MHz frequency), sonoporation was directly related to the bubble-to-cell ratio (in a range from 0 to 230). It was found that the nearest bubble-cell spacing was also related to the occurrence frequency of bioeffects. A constant bubble-to-cell ratio often provided very different results for two different initial cell concentrations (200,000 cells/mL and 600,000 cells/mL), with the higher cell concentration generally exhibiting higher levels of sonoporation. In contrast, a constant bubble-to-cell spacing provided similar results between the two initial cell concentrations. The frequency of reparable and lethal sonoporation was seen to decay as the inverse-cube power of the nearest bubble-cell spacing. Significant reparable sonoporation was observed at a bubble-cell spacing that was 10 microm larger than the minimum spacing at which significant lethal sonoporation was observed. Preliminary analysis also suggests the possibility of a step-wise increase in lethal sonoporation as spacing decreases; further experiment is needed.

Mesh:

Substances:

Year:  2000        PMID: 11053752     DOI: 10.1016/s0301-5629(00)00260-x

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  26 in total

1.  An experimental and theoretical analysis of ultrasound-induced permeabilization of cell membranes.

Authors:  Jagannathan Sundaram; Berlyn R Mellein; Samir Mitragotri
Journal:  Biophys J       Date:  2003-05       Impact factor: 4.033

2.  Contrast agent-free sonoporation: The use of an ultrasonic standing wave microfluidic system for the delivery of pharmaceutical agents.

Authors:  Dario Carugo; Dyan N Ankrett; Peter Glynne-Jones; Lorenzo Capretto; Rosemary J Boltryk; Xunli Zhang; Paul A Townsend; Martyn Hill
Journal:  Biomicrofluidics       Date:  2011-11-15       Impact factor: 2.800

3.  The role of acoustofluidics in targeted drug delivery.

Authors:  Nilanjana Bose; Xunli Zhang; Tapas K Maiti; Suman Chakraborty
Journal:  Biomicrofluidics       Date:  2015-08-20       Impact factor: 2.800

4.  Intracellular delivery of Bak BH3 peptide by microbubble-enhanced ultrasound.

Authors:  Manabu Kinoshita; Kullervo Hynynen
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

5.  Cavitation threshold of microbubbles in gel tunnels by focused ultrasound.

Authors:  Elisabetta Sassaroli; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2007-06-27       Impact factor: 2.998

6.  Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery.

Authors:  Z P Shen; A A Brayman; L Chen; C H Miao
Journal:  Gene Ther       Date:  2008-04-03       Impact factor: 5.250

7.  Driving delivery vehicles with ultrasound.

Authors:  Katherine W Ferrara
Journal:  Adv Drug Deliv Rev       Date:  2008-03-30       Impact factor: 15.470

8.  Acoustic Cavitation-Mediated Delivery of Small Interfering Ribonucleic Acids with Phase-Shift Nano-Emulsions.

Authors:  Mark T Burgess; Tyrone M Porter
Journal:  Ultrasound Med Biol       Date:  2015-05-13       Impact factor: 2.998

9.  Fluorescent microscope system to monitor real-time interactions between focused ultrasound, echogenic drug delivery vehicles, and live cell membranes.

Authors:  Stuart Ibsen; Michael Benchimol; Sadik Esener
Journal:  Ultrasonics       Date:  2012-05-28       Impact factor: 2.890

Review 10.  Ultrasound-mediated drug delivery for cardiovascular disease.

Authors:  Jonathan T Sutton; Kevin J Haworth; Gail Pyne-Geithman; Christy K Holland
Journal:  Expert Opin Drug Deliv       Date:  2013-03-01       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.